Trulieve Cannabis Corp. annual report, Q4 FY2020

Trulieve Cannabis Corp. — 2020 Form 10-K Summary

Business context and reporting period

Trulieve is a British Columbia corporation and multi-state cannabis operator reporting in U.S. dollars under U.S. GAAP for the year ended December 31, 2020. The company operated under licenses in six states, with substantially all revenue generated by its vertically integrated medical cannabis business in Florida. At year-end, Trulieve operated 70 Florida dispensaries, more than 1.9 million square feet of Florida cultivation facilities and employed 4,845 people.

Operations in Massachusetts, California, Connecticut, Pennsylvania and West Virginia were not yet material to consolidated revenue. The November 2020 acquisitions of PurePenn and Solevo Wellness expanded the company into Pennsylvania.

Financial performance and key metrics

Metric20202019Change
Revenue, net of discounts$521.5 million$252.8 millionUp 106%
Gross profit$386.4 million$191.8 millionUp 101%
Gross margin74%76%Down 2 percentage points
Income from operations$218.4 million$113.3 millionUp 93%
Net income$63.0 million$53.1 millionUp 19%
Basic diluted earnings per share$0.55 / $0.53$0.48 / $0.46Improved
Adjusted EBITDA$251.0 million$126.4 millionUp 99%
Net cash from operating activities$99.6 million$19.1 millionUp $80.6 million

Approximate derived margins were 41.9% for operating income, 12.1% for net income and 48.1% for Adjusted EBITDA in 2020. Adjusted EBITDA is a non-GAAP measure and includes substantial add-backs, including $94.5 million of income tax expense, $40.7 million of other expense and $20.2 million of net interest expense.

Cash and cash equivalents increased to $146.7 million from $91.8 million. Net cash used in investing activities was $174.7 million, principally reflecting acquisitions and purchases of property and equipment. Net cash provided by financing activities was $129.9 million, including $83.2 million of net proceeds from the September 2020 equity offering and $41.1 million from construction financing.

Total assets increased to $816.1 million from $386.0 million, while total liabilities increased to $368.2 million from $253.1 million. The balance sheet included $130.0 million of senior secured notes due in 2024, recorded net of issuance costs at $117.2 million, $6.0 million of other notes payable, $12.0 million of related-party notes payable and $82.0 million of construction finance liabilities. Operating and finance lease liabilities totaled $29.6 million and $38.9 million, respectively.

Material changes versus the prior comparable period

  • Revenue more than doubled, primarily due to organic retail growth, increased product availability, higher patient counts and the opening of 28 additional Florida dispensaries.
  • Gross margin declined from 76% to 74% because of higher depreciation, expansion into new markets, SAP implementation costs, inventory flow-through and product mix.
  • Sales and marketing expense increased 101% to $119.4 million, and general and administrative expense increased 156% to $36.1 million, reflecting additional personnel, infrastructure, compliance and expansion costs.
  • Other expense increased to $60.9 million, including approximately $42.7 million of warrant revaluation expense. On December 10, 2020, the public warrants were amended to U.S.-dollar exercise prices and reclassified to equity, eliminating the need for future revaluation expense for those warrants.
  • Income tax expense increased to $94.5 million. Section 280E limits deductions for cannabis businesses and contributed to a high cash tax burden.
  • Net cash from operations improved substantially, but capital investment and acquisitions consumed $174.7 million of investing cash flow.
  • Trulieve completed the PurePenn and Solevo Wellness acquisitions for upfront consideration of $66.0 million in cash and shares, with potential additional share-based earnouts of up to $65.0 million based on EBITDA milestones.
  • The September 2020 offering issued 4.715 million subordinate voting shares and generated approximately $83.2 million of net proceeds.

Guidance, outlook, risks and unusual items

Management’s stated priorities for the next 12 months were to expand Florida cultivation and production, complete and scale Massachusetts cultivation and processing, expand retail locations in Florida and Massachusetts, and enter additional markets. The filing does not provide quantified revenue, earnings or cash-flow guidance.

  • Massachusetts facilities and retail acquisitions remained subject to regulatory and local approvals. Pennsylvania cultivation capacity was expected to expand from 35,000 to 90,000 square feet in the first half of 2021.
  • Trulieve received four West Virginia dispensary permits in January 2021 and entered into an agreement in March 2021 to acquire a West Virginia cultivation license and two dispensary licenses, subject to regulatory approval.
  • Cannabis remains illegal under U.S. federal law. Potential consequences include federal enforcement, license loss, criminal or civil penalties, asset forfeiture and restrictions on contract enforcement.
  • Banking and financing access remain constrained because financial institutions may face federal anti-money-laundering exposure. The company relies on state-chartered banking relationships and lacks access to traditional bank financing.
  • Section 280E materially increases effective taxation because most ordinary business expenses are not deductible. The filing reports $50.6 million of 2020 tax expense attributable to Section 280E permanent differences.
  • The company is exposed to Florida concentration, regulatory changes, competition, agricultural and product-liability risks, cybersecurity threats, COVID-19 disruptions, cash-management risks and potential difficulty obtaining insurance.
  • Related-party matters include $12.0 million of related-party notes and $96.7 million of 2020 property and equipment purchases from a supplier partly owned by the CEO’s spouse. The company states that independent directors approved the supplier relationship.
  • A consolidated securities class action alleged misleading statements regarding financial statements and business prospects. The company’s motion to dismiss was granted on March 19, 2021; plaintiffs had until April 8, 2021 to amend. Management characterized the case as immaterial and without merit.
  • The company reported effective disclosure controls but, as an emerging growth company, did not include management’s assessment or an auditor attestation on internal control over financial reporting.

Most important facts for an investor to verify

  • Whether Florida market share, patient growth and new dispensary openings can offset margin pressure from expansion, product mix and operating costs.
  • The composition and maturity schedule of the $130.0 million senior secured notes, construction finance liabilities, lease obligations and related-party debt.
  • Cash taxes and the continuing impact of Section 280E on free cash flow and reported profitability.
  • Regulatory approvals, construction timelines and revenue contribution from Massachusetts, Pennsylvania and West Virginia.
  • Potential dilution from Pennsylvania earnouts, Massachusetts asset acquisitions, options, warrants and the company’s multiple-voting and super-voting share structure.
  • The status and potential exposure of the securities litigation and any other regulatory or legal proceedings.
  • The sustainability of Adjusted EBITDA after excluding warrant revaluation, taxes, interest, acquisition costs and other non-GAAP adjustments.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.